文献速递其他结缔组织病

接受环磷酰胺或自体造血干细胞移植治疗的系统性硬化症患者的皮肤细胞衰老与内皮-间质转化

Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究分析自体造血干细胞移植(aHSCT)或静脉环磷酰胺(iv CYC)治疗的弥漫性皮肤型系统性硬化症(dcSSc)患者治疗前后皮肤活检,发现两组均减轻皮肤增厚和内皮-间质转化(EndMT),但细胞衰老变化无显著差异,EndMT和uPAR与纤维重塑相关,衰老、CTGF、uPAR和血管分布与治疗反应相关。

要点

  • aHSCT组6个月改良Rodnan皮肤评分下降较iv CYC组更明显(中位变化-14 vs -6,P=0.028)。
  • 两组治疗后成纤维细胞uPAR、血管P21和EndMT均下降,aHSCT组下降更明显。
  • 皮肤反应差与基线成纤维细胞高CTGF(OR 1.43)和血管低P21(OR 0.41)相关。

核心结论

  • aHSCT和iv CYC均可在临床上减轻dcSSc皮肤增厚并减弱EndMT,但对细胞衰老的影响无显著差异。
  • EndMT和uPAR与纤维重塑活性相关,而衰老、CTGF、uPAR和血管分布与治疗反应相关。

研究设计与样本

  • 研究纳入自体造血干细胞移植国际硬皮病试验中接受aHSCT或iv CYC脉冲治疗的dcSSc患者,在随机化前和随机化后6个月收集皮肤活检。
  • 共分析14对皮肤活检,通过组织病理学检查纤维化、炎症、衰老、EndMT和组织重塑程度。

主要发现

  • aHSCT组6个月改良Rodnan皮肤评分中位变化为-14(IQR -16至-9),iv CYC组为-6(IQR -9至-4),P=0.028。
  • 两组治疗后成纤维细胞uPAR、血管P21和EndMT均下降,aHSCT组下降更明显。
  • 皮肤反应差与基线成纤维细胞高CTGF(OR 1.43)和血管低P21(OR 0.41)相关。
  • 治疗后成纤维细胞CTGF升高(OR 1.29)和血管P21升高(OR 3.02)的患者也出现反应差,P<0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cellular senescence and endothelial-to-mesenchymal transition (EndMT) are profibrotic cellular processes involved in systemic sclerosis (SSc), but how they respond to treatment is largely unknown. METHODS: Skin biopsies from diffuse cutaneous SSc (dcSSc) patients who underwent either autologous haematopoietic stem cell transplantation (aHSCT) or cyclophosphamide pulse (iv CYC) treatment were collected before and 6 months after randomization in the Autologous Stem Cell Transplantation International Scleroderma trial. The extent of fibrosis, inflammation, senescence, EndMT and tissue remodelling were examined in histopathology. RESULTS: Fourteen pairs of skin biopsies were analysed. Decrease in modified Rodnan skin score was more pronounced in aHSCT-treated patients compared with iv CYC at 6 months (median change -14 [IQR -16 to -9] vs -6 [IQR -9 to -4], respectively, P = 0.028). Histologically, expression of urokinase-type plasminogen activator receptor (uPAR) on fibroblasts, P21 on vessels and EndMT decreased after treatment in both groups, yet the reduction was more pronounced in the aHSCT group. Poor skin response was associated with high baseline connective tissue growth factor (CTGF) on fibroblasts and low baseline P21 on vessels, with an odds ratio (OR) of 1.43 and 0.41, respectively. Furthermore, poor response was also seen in patients with a rise in CTGF on fibroblasts (OR 1.29) and P21 on vessels (OR 3.02) after treatment, P < 0.001. CONCLUSION: Both aHSCT and iv CYC in dcSSc reduced skin thickening clinically and attenuated EndMT, but affected cellular senescence not significantly different. EndMT and uPAR were associated with fibro-remodelling activity, whereas senescence, CTGF, uPAR and vascularity were associated with treatment response.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chiu YH, van Dijk M, Goldschmeding R, et al. Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment. Rheumatology (Oxford). 2025. PMID: 39656818. doi:10.1093/rheumatology/keae660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。